J&J antes up on a $1B gamble that Theravance has the next blockbuster JAK for Crohn’s, ulcerative colitis
Even as Gilead $GILD and AbbVie $ABBV jockey for the lead in a compelling late-stage race to develop systemic JAK1 inhibitors for inflammatory bowel disease …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
